| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c4afb8b01aa8de7e0b24a86713b23a18 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-74 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-246
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24 |
| filingDate |
2015-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e17ab93cbd55ff6ccc9bce02ea7a04b1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b1e27709c80f85a70fbdce4dec9fb83
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6859cd17dadebd79d63196c10acc0c3 |
| publicationDate |
2017-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3166973-A1 |
| titleOfInvention |
Immune-stimulating monoclonal antibodies against human interleukin-2 |
| abstract |
The invention relates to a human lnterieuldn-2 (hIL-2) specific monoclonal antibody (mAb), or antigen binding fragment thereof, the binding of which to hlL-2 inhibits binding of hlL-2 to CD25 and the antibody is characterized by any of the parameters: the variable chain of the mAb comprises the amino acid sequence of SEQ ID NO 005 or SEQ ID NO 006; the binding to hIL-2 is characterized by a dissociation constant (K D )≤ 7,5 nmol/L; the binding to hIL-2 is characterized by an off-rate (Κ off )≤ 1x10 -4 s -1 and/or the antibody displays no measurable cross-reactivity to murine IL-2. |
| priorityDate |
2014-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |